An Open Label Extension Study of Multiple Subcutaneous Doses of LY2127399 in Patients With Rheumatoid Arthritis.
Phase of Trial: Phase II
Latest Information Update: 03 May 2018
At a glance
- Drugs Tabalumab (Primary)
- Indications Rheumatoid arthritis
- Focus Adverse reactions
- Sponsors Eli Lilly
- 10 Jun 2017 Biomarkers information updated
- 14 Nov 2012 Results presented at the 76th Annual Scientific Meeting of the American College of Rheumatology and the 47th Annual Meeting of the Association of Rheumatology and Health Professionals.
- 20 Mar 2012 Planned number of patients changed from 160 to 236 and additional location (Austria) added as reported by European Clinical Trials Database record.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History